 |
Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
HIV.gov | December 29, 2020 |
|
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
ViiV Healthcare | December 21, 2020
|
|
Update to CDC's Treatment for Gonococcal Infections, 2020
CDC | December 18, 2020
|
|
Fact Sheet for Recipients and Caregivers: Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older
FDA | December 2020
|
|
Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill
NPR | November 19, 2020
|
|
Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications
Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.
|
|
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Merck | November 16, 2020
|
|
Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg
FDA | November 2, 2020
|
|
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
PipelineReview.com | October 17, 2020
|
|
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
PipelineReview.com | October 16, 2020
|
|
Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment
POZ | October 16, 2020
|
|
Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients
BSA bureau | October 15, 2020
|
|
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel
Journal of the American Medical Association | October 14, 2020
|
|
Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In
POZ | October 9, 2020
|
|
Dentists, do you know which drugs do not mix with remdesivir?
Dr Bicuspid | October 8, 2020
|
|
Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified
PipelineReview.com | October 8, 2020
|
|
HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function
POZ | October 7, 2020
|
|
Injectable HIV therapy should save money if adherence is better than to oral therapies
aidsmap | October 7, 2020
|
|
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1 |
|
Gilead's Truvada faces Teva generics assault amid Descovy switching campaign
FiercePharma | October 2, 2020
|
|
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices
ViiV Healthcare | September 28, 2020
|
|
Pharmacists Play a Critical Role in Managing Changes to HIV Care During COVID-19
Pharmacy Times | September 16, 2020
|
|
Integrase Inhibitors Tied to Fewer Potentially Harmful Drug Interactions
POZ | August 31, 2020
|
|
FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling
FDA | August 6, 2020
|
|
Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial
Antimicrob Agents Chemother. 2020 Aug 3;AAC.00838-20. doi: 10.1128/AAC.00838-20
|
|
PREZCOBIX and EVOTAZ: Pediatric Label Updates |
|
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
The Lancet | July 25, 2020
|
|
EPCLUSA: updates to labeling (liver transplant) |
|
Long-acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study
NIH | July 7, 2020
|
|
Dolutegravir Use at Conception Not Tied to Neural Tube Defects After All
POZ | July 7, 2020
|
|
The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection
AIDS 2020: 23rd International AIDS Conference Virtual, July 6-10, 2020
|
|
HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men
IAC 2020 July 6-10 Virtual SF
|
|
New Findings on Gilead's Biktarvy Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
Financialbuzz.com | July 4, 2020
|
|
Clinical targeting of HIV capsid protein with a long-acting small molecule
Nature. 2020 Jul 1. doi: 10.1038/s41586-020-2443-1
|
|
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
BioSpace | July 2, 2020
|
|
Treatment Action Group’s 2020 HIV Pipeline Report
TAG | July 2020
|
|
RUKOBIA: New Drug Approved for HIV-1
FDA | July 2020
|
|
FDA expands Gardasil 9 approval for head and neck cancer prevention
Healio | June 15, 2020
|
|
Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research
Expert Opin Drug Deliv. 2020 Jun 17. doi: 10.1080/17425247.2020.1783233
|
|
FDA expands Gardasil 9 approval for head and neck cancer prevention
Healio | June 15, 2020
|
| |
|
|
|
FDA Approves Drug to Treat Infants and Children with HIV
FDA | June 12, 2020
|
|
Safety highlights from the DISCOVER Trial
Gilead | June 2020
|
|
Trivicay Now Available for Babies as Young as 4 Weeks
Infectious Disease Special Edition | June 12, 2020
|
|
National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2020 Annual Report
NASTAD | June 5, 2020
|
|
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
NIH | May 22, 2020
|
|
New COVID-19 CDC Resources on PrEP and Liver Disease
HIV.gov | May 21, 2020
|
|
NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men, and Transgender Women
HIV.gov | May 18, 2020
|
|
HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe
Infectious Disease Advisor | May 7, 2020
|
|
FDA authorizing the emergency use of remdesivir for treatment of COVID-19 |
|
Updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database
NASTAD | April 2020
|
|
NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate
NIH | April 2, 2020
|
|
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection
NCBI | March 2020
|
|
ADAP Advocacy Association Applauds Pharmaceutical Industry Efforts on Protecting the Drug Supply Chain during the Coronavirus Pandemic
ADAP Advocacy Association | March 26, 2020
|
|
ViiV Healthcare on Friday announced that Health Canada has approved Cabenuva (cabotegravir and rilpivirine)
The Pharma Letter | March 21, 2020
|
|
EPCLUSA: Labeling Updates for Pediatric Patients
FDA | March 19, 2019
|
|
Newer anti-HIV drugs safest, most effective during pregnancy
NIH | March 11, 2020
|
|
METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES
CROI 2020 March 11
|
|
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Gilead Sciences, Inc | March 9, 2020
|
|
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV | March 9, 2020
|
|
Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV
CROI 2020, March 8-11, 2020, Boston
|
|
Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch
CROI 2020, March 8-11, 2020, Boston
|
|
F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks
CROI 2020, March 8-11, 2020, Boston
|
|
Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP
CROI 2020, March 8-11, 2020, Boston
|
|
Maraviroc Does Not Demonstrate Clinical Benefit in Advanced HIV
Infectious Disease Advisor | March 5, 2020
|
|
SYMTUZA: Pediatric Labeling Updates
FDA | March 4, 2020
|
|
Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach
The New England Journal of Medicine | March 4, 2020
|
|
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
Gilead Sciences, Inc | November 8, 2019
|
|
A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have
ADAP Advocacy Association | February 27, 2020
|
|
Rockefeller grants commercial license for the development of new HIV drugs
Rockerfeller | February 26, 2020
|
|
The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis
Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
|
|
Adding maraviroc to standard treatment for advanced HIV does not improve outcomes
Healio | February 10, 2020
|
|
Just one dose of HPV vaccine may confer durable cervical cancer protection
Healio | February 10, 2020
|
|
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
abbvie | January 31, 2020
|
|
VEMLIDY: Labeling Updates
FDA | February 4, 2020
|
|
Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016
CDC | January 31, 2020
|
|
A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
NATAP | January 2020
|
|
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare | London, 10 January 2020
|
|
Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020
|
|
FDA Programs to Register HIV Drugs for Use in Resource-Constrained Settings
Infectious Disease Advisor | January 3, 2020
|
| |
|
|
